FDA approves expanded Botox (onabotulinumtoxinA) label to include eight new muscles to treat adults with upper limb spasticity

AbbVie

29 July 2021 - Botox has demonstrated efficacy and has an established safety profile with over 10 years of clinical use in adult upper limb spasticity

Allergan today announced that the U.S. FDA has approved a label expansion of Botox to include eight new muscles for the treatment of upper limb spasticity in adults. 

The new muscles for treatment include additional muscles of the elbow and forearm (brachialis, brachioradialis, pronator teres, and pronator quadratus), as well as intrinsic hand muscles (lumbricals and interossei) and thumb muscles (flexor pollicis brevis and opponens pollicis).

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , US